Synergy Pharmaceuticals Inc.

Novel approach for GI disease

We are developing unique analogs of the body’s natural gastrointestinal hormone – uroguanylin - a key regulator of normal physiology.

Learn more about Synergy’s Drug Pipeline

Leaders in our field

We have an experienced management team with industry expertise and a proven background of execution.

View our management team

Decisions based on data

We make every decision based on real data – it’s what drives the success of our clinical programs and our company.

Read about our clinical trials

Natural Analogs

Our approach is based on a key gastrointestinal hormone the body naturally produces to regulate normal digestive functioning - uroguanylin. Synergy scientists have discovered and developed two unique analogs of uroguanylin - plecanatide and SP-333 - designed to mimic the natural hormone's activity and target a variety of gastrointestinal conditions.

Learn more about Synergy's Approach

Drug Pipeline

Synergy’s Proprietary Platform

Both our lead drug, plecanatide, and our next-generation candidate, SP-333, are proprietary analogs of the body’s naturally occurring gastrointestinal (GI) hormone, uroguanylin, and represent a novel approach to the treatment of GI diseases and disorders. Plecanatide is in late stage clinical trials for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). SP-333 has successfully completed a phase 2 study in patients with opioid-induced constipation (OIC) and is currently being studied for treatment of ulcerative colitis (UC).

Learn More about Synergy's Drug Pipeline
Compound Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Marketed
SP-333 OIC
Go to News & Media

Latest News & Events

Go To Investor Relations

Investor Relations


Synergy Pharmaceuticals is a biopharmaceutical company focused on the development of new drugs to treat patients with gastrointestinal (GI) diseases and disorders.

Recent Documents

Market Cap